Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.40 |
| trials ClinicalTrials.gov | 12 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,168 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14504
Sealed predictions
- ATF1 in dopamine neurons, braak+0.23 (p 0.549) → -0.21 (p 0.591)receipt 14511
Swarm cases
receipt 14511: ATF1 in dopamine neurons, braak
- power
- full sample -0.06 (p 0.807, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.754, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.05 (p 0.834, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.05, sign flips 5; without severely affected donors -0.06 (p 0.807, n 18). fragile.
- cell type
- strongest in microglia: -0.62 (p 0.0064, n 18) vs -0.06 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATF1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ATF1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.13 p 0.657 (needs p < 1.6e-4)
Receipts
loading the receipts